PMC:7195088 / 18950-19130 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"665","span":{"begin":71,"end":79},"obj":"Species"},{"id":"771","span":{"begin":23,"end":41},"obj":"Chemical"},{"id":"772","span":{"begin":46,"end":54},"obj":"Chemical"},{"id":"926","span":{"begin":85,"end":93},"obj":"Disease"}],"attributes":[{"id":"A665","pred":"tao:has_database_id","subj":"665","obj":"Tax:9606"},{"id":"A771","pred":"tao:has_database_id","subj":"771","obj":"MESH:D006886"},{"id":"A772","pred":"tao:has_database_id","subj":"772","obj":"MESH:D019808"},{"id":"A926","pred":"tao:has_database_id","subj":"926","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"opinavir/ritonavir vs. hydroxychloroquine vs. losartan vs. placebos in patients with COVID-19. Double-blind, adaptive RCT (NCT04328012, not yet recruiting). Primary endpoint: NIAID"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T93","span":{"begin":85,"end":93},"obj":"Disease"}],"attributes":[{"id":"A93","pred":"mondo_id","subj":"T93","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"opinavir/ritonavir vs. hydroxychloroquine vs. losartan vs. placebos in patients with COVID-19. Double-blind, adaptive RCT (NCT04328012, not yet recruiting). Primary endpoint: NIAID"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T174","span":{"begin":9,"end":18},"obj":"Chemical"},{"id":"T175","span":{"begin":23,"end":41},"obj":"Chemical"},{"id":"T176","span":{"begin":46,"end":54},"obj":"Chemical"}],"attributes":[{"id":"A174","pred":"chebi_id","subj":"T174","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A175","pred":"chebi_id","subj":"T175","obj":"http://purl.obolibrary.org/obo/CHEBI_5801"},{"id":"A176","pred":"chebi_id","subj":"T176","obj":"http://purl.obolibrary.org/obo/CHEBI_6541"}],"text":"opinavir/ritonavir vs. hydroxychloroquine vs. losartan vs. placebos in patients with COVID-19. Double-blind, adaptive RCT (NCT04328012, not yet recruiting). Primary endpoint: NIAID"}

{"project":"LitCovid-sentences","denotations":[{"id":"T130","span":{"begin":95,"end":156},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"opinavir/ritonavir vs. hydroxychloroquine vs. losartan vs. placebos in patients with COVID-19. Double-blind, adaptive RCT (NCT04328012, not yet recruiting). Primary endpoint: NIAID"}